TY - JOUR
T1 - Treat-to-target in systemic lupus erythematosus: Where are we?
T2 - Where are we?
AU - Ríos-Garcés, Roberto
AU - Espinosa, Gerard
AU - van Vollenhoven, Ronald
AU - Cervera, Ricard
PY - 2020/4
Y1 - 2020/4
N2 - Systemic lupus erythematosus (SLE) is the most paradigmatic disorder within systemic autoimmune diseases. The concept and principles of treat-to-target (T2T) in SLE were established half a decade ago and, since then, remarkable advances have been made. An international consensus was organized in order to define and unify the term remission, although plurality, with subtle nuances still exists and has not been overcome. Also, lupus low disease activity state (LLDAS) was coined as an alternative and, perhaps, more realistic target. Both of them have proven to be meaningful in terms of improving several outcomes, and have opened the path for future research in clinical trials. This review arises from the need to summarize the current state of some of the recommendations of the T2T task force.
AB - Systemic lupus erythematosus (SLE) is the most paradigmatic disorder within systemic autoimmune diseases. The concept and principles of treat-to-target (T2T) in SLE were established half a decade ago and, since then, remarkable advances have been made. An international consensus was organized in order to define and unify the term remission, although plurality, with subtle nuances still exists and has not been overcome. Also, lupus low disease activity state (LLDAS) was coined as an alternative and, perhaps, more realistic target. Both of them have proven to be meaningful in terms of improving several outcomes, and have opened the path for future research in clinical trials. This review arises from the need to summarize the current state of some of the recommendations of the T2T task force.
KW - Low level disease activity
KW - Remission
KW - Systemic lupus erythematosus
KW - Treat-to-target in SLE
UR - http://www.scopus.com/inward/record.url?scp=85078844881&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ejim.2020.01.018
DO - https://doi.org/10.1016/j.ejim.2020.01.018
M3 - Review article
C2 - 32014364
SN - 0953-6205
VL - 74
SP - 29
EP - 34
JO - European Journal of Internal Medicine
JF - European Journal of Internal Medicine
ER -